Aligos Therapeutics ALGS

$ 20.11 1.62%

Quarterly report 2024-Q3
added 11-06-2024

Aligos Therapeutics Balance Sheet 2011-2024 | ALGS

Annual Balance Sheet Aligos Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-132 M	-78.1 M	-184 M	-207 M	-55.2 M	-10.2 M	-	-	-	-	-	-	-
Long Term Debt	231 K	230 K	261 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	3.23 M	3.04 M	2.77 M	2.44 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	15 M	198 M	114 M	-	-	-	-	-	-	-
Total Current Liabilities	23.9 M	33.1 M	39 M	30.3 M	-	-	-	-	-	-	-	-	-
Total Liabilities	59.4 M	42.8 M	50.6 M	45.3 M	211 M	121 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	7.89 M	-	-	-	-	-	-	-	-	-
Retained Earnings	-487 M	-399 M	-303 M	-175 M	-66.2 M	-13.9 M	-	-	-	-	-	-	-
Total Assets	152 M	147 M	235 M	265 M	147 M	108 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	136 M	81.3 M	187 M	220 M	70.1 M	-	-	-	-	-	-	-	-
Book Value	92.1 M	104 M	185 M	220 M	-64.9 M	-13.7 M	-	-	-	-	-	-	-
Total Shareholders Equity	92.1 M	104 M	185 M	220 M	-64.9 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Aligos Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	188 K	203 K	217 K	231 K	188 K	203 K	205 K	230 K	174 K	-	231 K	261 K	53 K	130 K	130 K	130 K	130 K	130 K	130 K	178 K	178 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	38.3 M	41.6 M	68.1 M	59.4 M	31 M	36.5 M	37 M	42.8 M	42.1 M	-	57.6 M	50.6 M	46.1 M	43 M	39.3 M	45.3 M	45.3 M	45.3 M	45.3 M	29.3 M	29.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.89 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-536 M	-517 M	-522 M	-487 M	-459 M	-441 M	-422 M	-399 M	-377 M	-	-339 M	-303 M	-265 M	-232 M	-202 M	-175 M	-175 M	-175 M	-175 M	-66.2 M	-66.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	88.4 M	109 M	128 M	152 M	85.9 M	106 M	122 M	147 M	164 M	-	210 M	235 M	263 M	212 M	235 M	265 M	265 M	265 M	265 M	147 M	147 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	35.3 M	45.1 M	24.2 M	136 M	70.4 M	90.8 M	78.7 M	81.3 M	86.4 M	71.2 M	105 M	187 M	240 M	188 M	200 M	220 M	220 M	220 M	220 M	69.6 M	69.6 M	-	-	24.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	50.1 M	67.2 M	59.8 M	92.1 M	54.8 M	69.6 M	84.8 M	104 M	122 M	-	153 M	185 M	217 M	169 M	195 M	220 M	220 M	220 M	220 M	117 M	117 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	50.1 M	67.2 M	59.8 M	92.1 M	54.8 M	69.6 M	84.8 M	104 M	122 M	137 M	153 M	185 M	217 M	169 M	195 M	220 M	220 M	220 M	220 M	-64.9 M	-64.9 M	-33.4 M	-	-13.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency